News

SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY

November 25, 2020

 

SBI Pharmaceuticals Co., Ltd.

TAGCyx biotechnologies Inc.

SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY

 

 

SBI Pharmaceuticals Co., Ltd., Tokyo, and TAGCyx biotechnologies Inc., Tokyo, announced entering into a research and develop collaboration to develop innovative products in the field of cancer treatment.

SBI Pharmaceuticals is specialized in the application of 5-ALA (5-aminolevulinic acid) and is dedicated to provide innovation for a wide range of health applications in the healthcare and health food field in order to help improve the health and quality of human life all over the world.

TAGCyx has invented artificial nucleic acid base-pair technology that enables to produce high affinity and selective DNA aptamers “Xenoligo®”.

By combining SBI Pharmaceuticals’ technology and TAGCyx’s Xenoligo®, both companies intend to develop novel technologies in oncology arena.

As part of the joint research and development, TAGCyx will receive research and development funds, multiple milestones at certain steps during the development as well as sales related royalties accordingly.

(*1) 5-aminolevulinic acid (5-ALA):  An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

 

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.:

Tel: 03-6229-0095  E-Mail:  info_ala@sbigroup.co.jp

 

TAGCyx biotechnologies Inc.

E-Mail:  info@tagcyx.com

Showa Denko Materials and the Drug Development Startup TAGCyx Sign a Commissioned Development Agreement on Regenerative Medicine Technologies

News Release

 

Showa Denko Materials Co., Ltd.
TAGCyx Biotechnologies Inc.
November 17, 2020

 

Showa Denko Materials and the Drug Development Startup TAGCyx Sign a Commissioned Development Agreement on Regenerative Medicine Technologies

Showa Denko Materials Co., Ltd. (President and CEO: Hisashi Maruyama; hereinafter “Showa Denko Materials”) and TAGCyx Biotechnologies Inc. (CEO: Chizuko Koseki; hereinafter “TAGCyx”) announce the signing of a commissioned development agreement on October 12, 2020 to apply TAGCyx’s proprietary technology to the regenerative medicine field.

TAGCyx is a venture firm developing DNA aptamer drugs based on its proprietary artificial nucleic acid base pair technology.* Aptamers are nucleic acid molecules (DNA or RNA) or peptides that bind three-dimensionally to specific molecules, and can be used as medications by acting specifically on target proteins in the same way as antibody drugs. TAGCyx developed “Xenoligo®” aptamers with high affinity and specificity for proteins, and utilizes this technology to generate drugs and conduct joint development with pharmaceutical companies.

Showa Denko Materials acquired 100 percent ownership of Minaris Regenerative Medicine, LLC (former PCT, LLC, a Caladrius Company), a leading contract manufacturer of regenerative medicine products in the United States, in May 2017, and has been expanding its regenerative medicine contract manufacturing business globally. Showa Denko Materials is also developing expendable supplies for regenerative medicine, such as induced pluripotent stem (iPS) cell culture media, along with innovative new products applicable to next-generation therapeutic modalities in the regenerative medicine field.

Under this commissioned development agreement, Showa Denko Materials will commission TAGCyx with the development of new technologies related to regenerative medicine by applying the Xenoligo® platform. The two companies aim to create safe and highly effective cell therapy preparations based on the outcomes of their joint development project.

*Artificial nucleic acid base pair technology involves a system that adds a third artificial base pair to two natural DNA base pairs (adenine (A) paired with thymine (T) and guanine (G) paired with cytosine (C)), with research and development advancing worldwide as technologies innovating basic systems in molecular biology. Among them, TAGCyx’s proprietary artificial base pairing technology leads the world providing high fidelity amplification capability in polymerase chain reaction (PCR).

Ms. Yukari Ikeda received the Seven Star Pharmacist candidate Award for the results of skin penetration of our anti-IFNγ aptamer.

Ms. Yukari Ikeda (Tokyo University of Pharmacy and Life Sciences, Dr. Takashima’s Lab) received the Seven Star Pharmacist candidate Award from the Nagai Foundation Tokyo in the Academy of Pharmaceutical Science and Technology, Japan.

She reported the results of skin penetration of TAGX-0003 (anti IFNγ aptamer) using ionic liquid as DDS at the 35th annual meeting of the Academy of Pharmaceutical Science and Technology, Japan.